

Date: 6th August 2026
Ref: CORP 26/27 - 065

Dear xxx

Freedom of Information request: Treatment of Endometrial Cancer (CORP 26/27 – 065)

Thank you for your request for information which the Trust received on 9th July 2026.

Your Request:

1. *How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:*
 - Dostarlimab (Jemperli)
 - Dostarlimab (Jemperli) + Chemotherapy
 - Hormone therapy (Progesterone or Letrozole)
 - Lenvatinib + Pembrolizumab (Keytruda + Lenvima)
 - Pembrolizumab monotherapy (Keytruda)
 - Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
 - Durvalumab with Platinum-based Chemotherapy
 - Pembrolizumab with Platinum-based Chemotherapy
 - Any other SACT
 - If the Trust are using **Pembrolizumab subcutaneous injection**, please can you provide the number of patients who received treatment with **Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy**
2. *Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.*

Please find the Trust's response below:

1. **How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:**
 - Dostarlimab (Jemperli)
 - Dostarlimab (Jemperli) + Chemotherapy
 - Hormone therapy (Progesterone or Letrozole)
 - Lenvatinib + Pembrolizumab (Keytruda + Lenvima)
 - Pembrolizumab monotherapy (Keytruda)
 - Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
 - Durvalumab with Platinum-based Chemotherapy
 - Pembrolizumab with Platinum-based Chemotherapy

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



- **Any other SACT**
- **If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy**

The Trust does not hold the requested information in a format that allows it to be readily extracted at the level of detail required. Responding to this part of your request would therefore require a manual review of records.

We estimate that completing this work would take at least 22 hours, at a cost of £550. This exceeds the appropriate limit of £450 by £100. The full fee would need to be paid before the Trust could undertake the work.

The Trust is therefore applying the exemption under Section 12 of the Freedom of Information Act 2000, which applies where the cost of compliance exceeds the appropriate limit. The legislation states:

12 Exemption where cost of compliance exceeds appropriate limit.

(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

Under Section 16 of the Act, the Trust has a duty to provide advice and assistance. You may therefore wish to refine your request so that it can be answered within the appropriate cost limit.

- 2. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.**

ACTOv Study

Full title: A multicentre phase II randomised controlled trial to evaluate the efficacy of Adaptive Therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high grade serous or high grade endometrioid ovarian cancer.


Number of participants recruited: <6*

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.





Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Information Commissioner's Office - Wales
2nd Floor,
Churchill House,
Churchill Way,
Cardiff,
CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk

Non Gwilym
Interim Director of Corporate Governance
Velindre University NHS Trust
2 Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

CYNTHIA AND
 CONNOR'S WEDDING
 PLANNING + PLATFORM
 Cynthia and
 Connor's
 Wedding Plans

